Day: October 26, 2021

As stated in paragraph 6 in General Terms of Auction for Treasury bonds, the Government Debt Management offered the equivalent of 10% of the nominal value sold in the auction 22. October, at the price of accepted bids.Series RIKB 25 0612 RIKS 26 0216ISIN IS0000019321 IS0000030732Additional issuance (nominal) 0 0Total outstanding (nominal) 102,695,963,000 44,671,700,000

 Innofactor Plc ANNOUNCEMENT 10/26/2021          INNOFACTOR PLC: SHARE REPURCHASE 10/26/2021       In the Helsinki Stock Exchange         Trade date 10/26/2021  Bourse trade Buy  Share IFA1V  Amount 30,000 SharesAverage price/ share 1.5822 EURTotal cost 47,466.00 EUR          Innofactor Plc now holds a total of 30 000 sharesincluding the shares repurchased on 10/26/2021          On behalf of Innofactor Plc         Nordea Bank Oyj         Janne Sarvikivi Sami Huttunen       Additional information:    Sami Ensio, CEO    Innofactor Plc    Tel. +358 50 584 2029    sami.ensio@innofactor.com         www.innofactor.com           AttachmentInnofactor_26.10_trades

RaySearch Laboratories AB (publ) and IBA announce that they expanded their partnership in proton therapy within the areas of flash radiotherapy, proton ARC therapy, and treatment of moving tumors.   Louvain-La-Neuve, Belgium, 26 October 2021 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, today announces RaySearch Laboratories AB (publ) and IBA expand their partnership in proton therapy within the areas of flash radiotherapy, proton ARC therapy, and treatment of moving tumors IBA and RaySearch have had a strategic partnership on a global level since 2013. Over the years the collaboration has deepened and the combination of RayStation® and IBA’s Proteus® systems are nowadays a well proven and de facto industry standard. As of today, the majority of IBA’s Proteus® centers have selected RayStation®...

Fifth Phase II trial of UV1 in cancer, and largest disease category to date UV1 will be investigated in combination with the standard-of-care pembrolizumab Expected data read-out by end of 2024OSLO, Norway, Oct. 26, 2021 (GLOBE NEWSWIRE) — Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announced that the company’s universal cancer vaccine, UV1, will be investigated in a new Phase II clinical trial in combination with pembrolizumab in non-small cell lung cancer (NSCLC). The first patient is expected to be treated in H1 2022, with data read-out from the trial, LUNGVAC, anticipated by the end of 2024. Lung cancer is currently one of the most common cancers globally, and by far the biggest cause of cancer deaths in both men and women. NSCLC accounts for approximately...

Sandusky, OH, Oct. 26, 2021 (GLOBE NEWSWIRE) — PAO Group, Inc. (OTC Pink: PAOG) today announced the company’s merger and acquisition development pipeline supports plans for a first acquisition to close before the end of this year.  PAOG is actively exploring merger and acquisition opportunities targeted at expanding the company’s product line and accelerating revenue growth. The company recently announced initiating production on its first line of CBD nutraceuticals and being on track to generate its first revenue this year, in 2021, since entering the CBD market sector. PAOG has introduced its first to CBD nutraceutical products, RelaxRX and RehabRX.  PAOG is developing a “RX” CBD nutraceuticals brand. PAOG is developing CBD pharmaceutical and nutraceuticals from its intellectual property associated with a patented cannabis extraction...

Company Receives Honor Fourth Consecutive Year from the Women in Trucking Association OVERLAND PARK, Kan., Oct. 26, 2021 (GLOBE NEWSWIRE) — Yellow Corporation (NASDAQ: YELL) has been honored again by the Women in Trucking Association among its “Top Companies for Women to Work for in Transportation.” WIT recognizes companies with corporate cultures that foster gender diversity and also offer competitive compensation and benefits, flexible hours and work requirements, professional development opportunities and career advancement opportunities. WIT established the “Top Companies for Women to Work for in Transportation” award to support and advance its mission to encourage the employment of women in the trucking industry, promote their accomplishments, and minimize obstacles faced by women working in the trucking industry. “What an...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, SOUTH AFRICA, NEW ZEALAND, JAPAN OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL Ultimovacs ASA – Contemplated private placement With reference to the stock exchange notice dated 26 October 2021 – “Ultimovacs to Launch Phase II Combination Trial of UV1 in Lung Cancer (NSCLC)”, Ultimovacs ASA (“Ultimovacs” or the “Company”) announces an intention to carry out a private placement with gross proceeds of approximately NOK 225 to 270 million (the “Private Placement”) by issuing new shares (the “Offer Shares”). The final size of the Private Placement and the number of Offer...

Cambridge, MA, Oct. 26, 2021 (GLOBE NEWSWIRE) — Peer To Peer Network a.k.a MobiCard Inc. (OTC PINK: PTOP) is happy to announce that on Tuesday 10/25/2021 we have resubmitted our Mobicard apps back to their respective app stores for review with the goal of being published and back in the stores again soon. The audit could take a couple of months, or it may be expedited and take only a few weeks. It is in the app stores hands now. PTOP MobiCard (otc: PTOP) (@freemobicard) / Twitter will be hosting a TwitterSpaces on this Thursday 10/28/21 at 7pm EST to address any questions, comments, concerns, or suggestions. This Thursday, PTOP’s tech team will be hosting a TwitterSpaces at 7pm Eastern Standard Time to discuss the technical side of MobiCard. It will be hosted by our CTO Nicholis Santana, and he will be joined by our Principal Software...